• br Materials and Methods br Results A total of NSCLC

  2024-09-21

  

  Materials and Methods Results A total of 28 NSCLC tumor samples from 26 patients (2 patients with paired tumor samples) were included. According to the initial FISH (Abbott Molecular probes) and IHC results, 13 samples were ALK IHC+FISH+, 5 samples were ALK IHC+FISH−, 2 samples (from the same

• Blockers will reduce perioperative myocardial ischemia

  2024-09-21

  

  β-Blockers will reduce perioperative myocardial ischemia and studies published in the 1990s suggested that their routine administration before surgery provided protection against perioperative CV complications.31., 32., 33. Based on these early studies, several national organizations endorsed the pe

• It has been reported that HT R involves

  2024-09-21

  

  It has been reported that 5-HT2R involves in type 2 diabetes mellitus and 5-HT-induced IR [22,23]. The present study also demonstrated that it is 5-HT2R rather than other 5-HT receptors, including 5-HT1BR and 5-HT7R, in the liver that mediates HFD-induced abnormality of hepatic lipid metabolism, and

• Pituitary adenylate cyclase activating polypeptide PACAP is

  2024-09-21

  

  Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as

• AdipoRon is an orally active synthetic small molecule that a

  2024-09-21

  

  AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r

• br Introduction Adenosine deaminase ADA which can

  2024-09-21

  

  Introduction Adenosine deaminase (ADA), which can catalyze the conversion of AD to inosine by removing an amino group, is a key hydrolytic enzyme of purine metabolism (Conway and Cooke, 1939), and plays an important role in an amount of diseases. For example, an increase of ADA activity in serum

• A correlation analysis was performed to investigate a

  2024-09-21

  

  A correlation analysis was performed to investigate a possible relationship between serum resistin levels and MG-ADL. We observed a significant relationship between serum resistin levels and MG-ADL scores in AChR-GMG-positive cases (r=0.285, p=0.032; Fig. 1C). There were also significant correlation

• Apoptosis or programmed cell death

  2024-09-21

  

  Apoptosis or programmed cell death is a function of biochemical mechanisms, which are energy-dependent. It is considered to be a vital component of many processes such as normal cell cycle, immune mechanism, atrophy, embryonic development and toxin-induced cell death (Elmore, 2007). In addition, apo

• br Disclaimer br Conflicts of interest br Role of

  2024-09-21

  

  Disclaimer Conflicts of interest Role of the Sponsor Acknowledgements Funding/support: This project was supported by a grant from the Department of Surgery (R5129), Western University and by the Institute for Clinical Evaluative Sciences (ICES) Western site. ICES is funded by an annual g

• Jesus et al discovered a new

  2024-09-20

  

  Jesus et al. discovered a new series of azaindole as Aurora inhibitors through various modification of GSK1070916 (47). They synthesized series from modification of the GSK1070916 and evaluated for in-vitro Aurora-B/INCENP and Aurora-A/TPX2 inhibition assays. Modified Formoterol Hemifumarate 48 and

• IGF is an anabolic growth factor that induces

  2024-09-20

  

  IGF1 is an anabolic growth factor that induces hypertrophy and blocks atrophy in skeletal muscle by activating the PI3K/AKT/mTOR pathway (Egerman and Glass, 2014). In addition to its anabolic and anti-catabolic effects, IGF1 stimulates fatty nicotinic receptor agonist (FA) uptake and glucose metabo

• br Conflict of interest statement br

  2024-09-20

  

  Conflict of interest statement Funding Acknowledgments We thank the team at Medical and Collider-Accelerator Departments at BNL and for their support at NSRL. We thank Dr. Janice Pluth and Professor Peter O’Neill for useful discussions related to our work. Introduction The DNA damage re

• br Funding This study was

  2024-09-20

  

  Funding This study was supported by Grant UM1-CA186690 (NCI-CTEP) and R01CA204173 (CJB). This project used the UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) and was supported in part by award P30-CA47904 and R50CA211241. Introduction Despite the efficacy of platinum based

• Our results clearly demonstrate that

  2024-09-20

  

  Our results clearly demonstrate that inhibition of ATM pathway activation results in resistance to Vγ2Vδ2 T cell-mediated cell death. Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treatment would promote the cytotoxicity of resistant ovarian cancer cells. To our knowledge, this is the

• br Emerging Vascular Mechanisms of AA Therapy Resistance

  2024-09-20

  

  Emerging Vascular Mechanisms of AA Therapy Resistance Experimental and clinical evidence indicates that physiological angiogenesis generates blood vessels capable of restoring perfusion [1], whereas tumoral angiogenesis gives rise to vessels that are structurally and functionally abnormal, therei

16572 records 86/1105 page Previous Next First page 上5页 8687888990 下5页 Last page